Array BioPharma was founded in 1998 and is headquartered in Boulder, US

Array BioPharma has offices in Boulder, Cambridge, Morrisville, Houston and in 7 other locations

Boulder, US (HQ)

3200 Walnut St

Morrisville, US

115 3005 Carrington Mill Blvd

Cambridge, US

301 125 Cambridge Park Dr

Array BioPharma's revenue was reported to be $33.3 m in Q3, 2017

USD

## Revenue (Q3, 2017) | 33.3 m |

## Net income (Q3, 2017) | (35.3 m) |

## EBIT (Q3, 2017) | (31.9 m) |

## Market capitalization (21-Jul-2017) | 1.4 b |

## Cash (30-Jun-2016) | 56.6 m |

Array BioPharma's current market capitalization is $1.4 b.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 42.1 m | 51.9 m | 137.9 m |

## Revenue growth, % | 23% | 166% | |

## Gross profit | (3.9 m) | 7.5 m | |

## Gross profit Margin, % | (9%) | 14% | |

## Operating expense total | 117.7 m | 130.3 m | 220.1 m |

## EBIT | (75.6 m) | 3.3 m | (82.2 m) |

## EBIT margin, % | (180%) | 6% | (60%) |

## Net Income | (85.3 m) | 9.4 m | (92.8 m) |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 35.4 m | 43 m | 39.3 m | 44.5 m | 33.3 m | ||||

## General and administrative expense | 9.9 m | 8.4 m | 7.9 m | 8.8 m | 11.7 m | ||||

## Operating expense total | 9.9 m | 8.4 m | 7.9 m | 8.8 m | 11.7 m | ||||

## EBIT | (21.5 m) | (20 m) | (24 m) | (19.8 m) | (31.9 m) | ||||

## EBIT margin, % | (61%) | (46%) | (61%) | (44%) | (96%) | ||||

## Interest expense | (2.7 m) | (2.7 m) | (3 m) | (3.1 m) | (3.1 m) | ||||

## Interest income | 51 k | 76 k | 70 k | 212 k | 228 k | ||||

## Net Income | (27.6 m) | (36.2 m) | 22.1 m | (21 m) | (24.2 m) | (22.7 m) | (28.6 m) | (23.3 m) | (35.3 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 68.6 m | 55.7 m | 56.6 m |

## Accounts Receivable | 5.4 m | 6.3 m | 39.3 m |

## Inventories | 5.2 m | 6.4 m | 6.1 m |

## Current Assets | 121.7 m | 191 m | 155.3 m |

## PP&E | 8.2 m | 5.1 m | 6.7 m |

## Total Assets | 139.1 m | 198.2 m | 168.9 m |

## Accounts Payable | 7 m | 4.6 m | 10.1 m |

## Current Liabilities | 52.7 m | 42.4 m | 52.4 m |

## Non-Current Liabilities | 112 m | 113.1 m | 154.4 m |

## Total Liabilities | 164.8 m | 155.6 m | 206.8 m |

## Additional Paid-in Capital | 652.7 m | 711.7 m | 763.3 m |

## Retained Earnings | (717.9 m) | (708.6 m) | (801.4 m) |

## Total Equity | (25.7 m) | 42.7 m | (37.9 m) |

## Financial Leverage | -5.4 x | 4.6 x | -4.5 x |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} |
---|---|---|---|---|

## Cash | 46.8 m | 68.1 m | 141.5 m | 56.4 m |

## Accounts Receivable | 6 m | 4.9 m | 2.1 m | 13.5 m |

## Current Assets | 122.8 m | 150.8 m | 196.6 m | 179.6 m |

## PP&E | 7.8 m | 8.1 m | 7.5 m | 5 m |

## Total Assets | 135.3 m | 163.6 m | 208.4 m | 186.8 m |

## Accounts Payable | 5.2 m | 9.3 m | 7.6 m | 6.5 m |

## Current Liabilities | 56.6 m | 67.9 m | 44.9 m | 49.3 m |

## Non-Current Liabilities | 116.3 m | 109.6 m | 113.4 m | 113.4 m |

## Additional Paid-in Capital | 653.9 m | 687.2 m | 696.7 m | 753.5 m |

## Retained Earnings | (745.5 m) | (754.1 m) | (695.8 m) | (729.6 m) |

## Total Equity | (37.6 m) | (13.9 m) | 50.2 m | 24.1 m |

## Financial Leverage | -3.6 x | -11.8 x | 4.2 x | 7.7 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (85.3 m) | 9.4 m | (92.8 m) |

## Depreciation and Amortization | 4.5 m | 3.7 m | 1.5 m |

## Accounts Receivable | 4.2 m | (7.6 m) | (33 m) |

## Cash From Operating Activities | (71.7 m) | (5.8 m) | (70.1 m) |

## Purchases of PP&E | (2.6 m) | (2.5 m) | (3.2 m) |

## Cash From Investing Activities | 2.5 m | 66 m | |

## Cash From Financing Activities | 77.1 m | 50.9 m | 5 m |

## Interest Paid | 4.3 m | 4.5 m | 4.5 m |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (27.6 m) | (36.2 m) | 22.1 m | (21 m) | (24.2 m) | (22.7 m) | (28.6 m) | (23.3 m) | (35.3 m) |

## Depreciation and Amortization | 876 k | 1.8 m | 2.8 m | 473 k | |||||

## Accounts Receivable | (571 k) | 551 k | (3.4 m) | (7.2 m) | 64.8 m | 62.9 m | 33.9 m | 43.1 m | 32.5 m |

## Accounts Payable | 12.1 m | 15.6 m | 5.9 m | 6.5 m | 7.8 m | ||||

## Cash From Operating Activities | (18.8 m) | (16.8 m) | 21.5 m | (19.2 m) | |||||

## Purchases of PP&E | (483 k) | (1.7 m) | (2.1 m) | (411 k) | |||||

## Cash From Investing Activities | (3 m) | (15 m) | |||||||

## Cash From Financing Activities | 45 k | 31.3 m | 38.8 m | 664 k | |||||

## Interest Paid | 121 k | 2.2 m | 2.3 m | 121 k |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 188 k |